{
  "source": "PA-Notification-Evrysdi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1328-7\nProgram Prior Authorization/Notification\nMedication Evrysdi® (risdiplam)\nP&T Approval Date 9/2020, 9/2021, 7/2022, 8/2023, 7/2024, 12/2024, 4/2025\nEffective Date 6/1/2025\n1. Background:\nEvrysdi is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of\nspinal muscular atrophy (SMA) in pediatric and adult patients.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Evrysdi will be approved based on all of the following criteria:\na. Diagnosis of spinal muscular atrophy (SMA)\n-AND-\nb. Patient is not receiving concomitant chronic survival motor neuron (SMN) modifying\ntherapy [e.g., Spinraza (nusinersen)]\n-AND-\nc. One of the following:\n(1) Patient has not previously received gene replacement therapy for the treatment of\nSMA [e.g., Zolgensma (onasemnogene abeparvovec-xioi)]\n-OR-\n(2) Both of the following:\n(a) Patient has previously received gene replacement therapy [e.g., Zolgensma\n(onasemnogene abeparvovec-xioi)] for the treatment of SMA\n-AND-\n(b) Submission of medical records (e.g., chart notes, laboratory values) documenting\na clinically meaningful functional decline (e.g., loss of motor milestone) since\nreceiving gene replacement therapy [e.g., Zolgensma (onasemnogene\nabeparvovec-xioi)]\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n1\nB. Reauthorization\n1. Evrysdi will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Evrysdi therapy\n-AND-\nb. Patient is not receiving concomitant chronic survival motor neuron (SMN) modifying\ntherapy [e.g., Spinraza (nusinersen)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria",
    "member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Medical Necessity and/or Supply limits may be in place.\n4. References:\n1. Evrysdi [package insert]. South San Francisco, CA: Genentech, Inc; September 2024.\nProgram Prior Authorization/Notification – Evrysdi (risdiplam)\nChange Control\n9/2020 New program\n9/2021 Annual review with no changes to clinical coverage criteria. Updated\nreference.\n7/2022 Updated criteria to align with new labeled indication in patients of all\nages. Added state mandate and updated reference.\n8/2023 Annual review. Updated reference.\n7/2024 Annual review. Updated reference.\n12/2024 Added criteria for patients that have documented decline from\npretreatment baseline status following administration of gene\nreplacement therapy. Updated reference.\n4/2025 Revised criteria for patients that have documented decline from\npretreatment baseline status following administration of gene\nreplacement therapy.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}